Upcoming Webinar: Salt-tolerant endonucleases and the benefits for viral vector manufacturing, and a comparison of two marketed enzymes

Upcoming Webinar: Salt-tolerant endonucleases and the benefits for viral vector manufacturing, and a comparison of two marketed enzymes

Tuesday 27th August 2024
08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST

Live30 webinars are thirty-minute presentations designed to update you on the latest innovations, applications, and data in a fast yet interactive format. 

Recombinantly produced Serratia marcescens endonucleases, such as DENARASE®, are commonly applied for DNA removal in viral vector manufacturing processes. To further improve the solubility and thus manufacturing efficacy of viral vectors, higher salt concentrations can be applied. However, the activity of the commonly applied Serratia marcescens endonucleases is inhibited at higher salt concentrations. For this reason, producers of viral vectors increasingly look at alternative, more salt-tolerant endonucleases for nucleic acid digestion.

In this webinar, we want to introduce DENARASE® High Salt, an engineered variant of the Serratia marcescens wild-type enzyme. We will describe how the enzyme was optimized to become more tolerant to higher salt concentrations and explain how these conditions can streamline the viral vector manufacturing process. In addition, we will show data generated by a cell and gene therapy CDMO that compared DENARASE® High Salt with another commercially available salt-tolerant endonuclease (SAN HQ) in an AAV2 harvest.

  • The benefits of higher salt concentrations in viral vector manufacturing

  • The art and power of enzyme engineering

  • How salt-tolerant endonucleases enable leaner viral vector processing

  • A performance comparison of commercially available salt-tolerant endonucleases


Presenters:

Marc Struhalla, PhD // CEO // View Biography

Svenja Michalek, PhD // Product Manager Biopharma // View Biography